Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Debt

The Debt of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 2, 2026 is 31.48 M CNY. In the previous year, Debt was 1.62 B CNY — a change of -98.06% (lower).

Debt

31.48 MCNY

YoY

-98.06%

Last updated:

In 2025, Harbin Pharmaceutical Group Co's total debt was 31.48 M CNY, a -98.06% change from the 1.62 B CNY total debt recorded in the previous year.

The Harbin Pharmaceutical Group Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
254.18 M CNY
Jan 1, 2019
673.08 M CNY
Jan 1, 2020
1.77 B CNY
Jan 1, 2021
2.31 B CNY
Jan 1, 2022
2.16 B CNY
Jan 1, 2023
1.72 B CNY
Jan 1, 2024
1.62 B CNY
Jan 1, 2025
31.48 M CNY
The Harbin Pharmaceutical Group Co Debt history
YEARDebtYoY
31.48 MCNY-98.06%
1.62 BCNY-5.82%
1.72 BCNY-20.18%
2.16 BCNY-6.74%
2.31 BCNY+30.41%
1.77 BCNY+163.52%
673.08 MCNY+164.80%
254.18 MCNY-3.06%
262.20 MCNY+76.81%
148.29 MCNY-24.97%
197.65 MCNY+19.99%
164.73 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Harbin Pharmaceutical Group Co's Debt Structure

Harbin Pharmaceutical Group Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Harbin Pharmaceutical Group Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Harbin Pharmaceutical Group Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Harbin Pharmaceutical Group Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Debt of Harbin Pharmaceutical Group Co is 31.48 M CNY in 2025.

Debt of Harbin Pharmaceutical Group Co changed from 1.62 B CNY to 31.48 M CNY, representing a -98.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Harbin Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Harbin Pharmaceutical Group Co